Literature DB >> 6235744

Abnormalities of lymphocyte subsets are correlated with concentrate consumption in asymptomatic Italian hemophiliacs treated with concentrates made from American plasma.

P M Mannucci, A Gringeri, M Ammassari, D Mari.   

Abstract

Eighty-three symptom-free hemophiliacs were studied clinically, serologically and by in vitro tests for cellular immunity in a geographical area in which AIDS has not yet been encountered despite the exclusive use of concentrates manufactured from American sources of plasma. Some patients showed the following abnormalities: lymphopenia (4%), decreased T-helper/T-suppressor (Th/Ts) cell ratios (49%), or both abnormalities (2%). Low Th/Ts were mostly due to absolute or, less frequently, relative increases in Ts cells. The prevalence rates for these abnormalities were the same in patients treated with factor VIII or factor IX concentrates. There was an association between the higher Ts and lower Th cells counts and the low Th/Ts ratios and greater annual consumption of factor VIII and factor IX concentrates. These results support the view that protein load might be an important pathogenetic factor in lymphocyte abnormalities in symptom-free hemophiliacs.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6235744     DOI: 10.1002/ajh.2830170208

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  2 in total

1.  Abnormalities of in vitro immunoglobulin production in apparently healthy haemophiliacs: relationship with alterations of T cell subsets and with HTLV-III seropositivity.

Authors:  R Biagiotti; M G Giudizi; F Almerigogna; M Mazzetti; A Alessi; G F Del Prete; D Rafanelli; M Fiorilli; M Morfini; S Romagnani
Journal:  Clin Exp Immunol       Date:  1986-02       Impact factor: 4.330

Review 2.  Progressive change in lymphocyte distribution and degree of hypergammaglobulinemia with age in children with hemophilia.

Authors:  B T Shannon; J Roach; M Cheek-Luten; C Orosz; F B Ruymann
Journal:  J Clin Immunol       Date:  1986-03       Impact factor: 8.317

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.